News >

Expert Says Paradigm Shift Imminent in SCLC

Angelica Welch
Published: Thursday, Jun 07, 2018

Anne Chiang, MD, PhD

Anne Chiang, MD, PhD
Immunotherapy has the potential to change the treatment paradigm of small cell lung cancer (SCLC), said Anne Chiang, MD, PhD. Moreover, recent results with immunotherapy agents in the second-line setting have already influenced guidelines.

, Chiang, a professor and thoracic oncologist at Yale Cancer Center, discussed recent developments with immunotherapy and the overall outlook for the treatment landscape of SCLC.

OncLive: Can you provide some insight on the current treatment landscape of SCLC?

Chiang: The landscape has changed, and that is something that is very new for SCLC because it hasn't changed that much in the past 30 years. Right now, the standard of care is giving a platinum doublet upfront for extensive-stage disease, and cisplatin and etoposide for limited-stage disease concurrent with radiation.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 2nd Annual School of Nursing Oncology™Sep 28, 20191.5
Medical Crossfire®: Experts Weigh-In on Emerging Immune Checkpoint Inhibitors and Combination Strategies for Advanced NSCLCNov 30, 20191.5
Publication Bottom Border
Border Publication